CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financia

A New Mexico jury ruled that Meta (formerly Facebook) violated state consumer protection laws by misleading users about privacy and content moderation, citing false claims about data control and hate speech policies. The verdict follows a trial focused on the Cambridge Analytica scandal, with over 44 million violations found. Meta disputes the ruling and plans to appeal. Fines could reach $5,000 per violation, with a hearing scheduled.

Diagnos Inc. (TSXV: ADK, OTCQB: DGNOF, FWB: 4D4A) submitted a request to the FDA for regulatory classification of its CARA System, an AI-powered tool for retinal image analysis. The submission is part of its U.S. regulatory strategy, aiming to access a market of 49,500 optometrists. The system is already licensed in Canada and Saudi Arabia.

Iowa Attorney General Brenna Bird announced a $35M settlement with Corteva, Inc. over alleged monopoly violations in its pesticide loyalty programs. Iowa will receive $2.4M. The FTC and states claimed Corteva's practices limited competition, raising farmers' costs. The settlement is separate from an $85M class action case involving over 100,000 farmers.

Merck (MRK) and Daiichi Sankyo withdrew a U.S. approval application for their investigational cancer drug, citing insufficient data. Merck's stock is at $148.74, with a mid-target of $166 and a potential 12% total return. The company's pipeline is estimated to deliver $70B+ by the mid-2030s, but recent setbacks highlight risks. Analysts' FY2030 revenue estimates have risen to around $76B.

Portland General Electric (POR) received regulatory approval to restructure under a holding company model, including an $83M rate credit and customer benefits, but faces new operational constraints. The company's P/S ratio is 1.53x, below its historical median, reflecting market skepticism. Insider activity shows net selling, and the GF Score is 81/100, indicating solid fundamentals despite financial risks.